Multiple Myeloma: Immunodeficient, Osteolytic, Renal, and Amyloid Syndromes

  • V. A. Almazov
  • E. I. Podoltzeva
  • E. V. Morozova
  • X. O. Sitskaya
  • V. M. Kravzova
  • B. V. Afanasiev
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 35)

Abstract

Multiple myeloma (MM) is a malignant clonal B-lymphoproliferative disease with typical immunodefficient, osteolytic, renal, amyloid syndromes. Disturbance in the immunologic system appears early and influences the outcome of MM [1]. Light chain isotype suppression (LCIS) [2] and imbalance in T-cells [3] are the factors determining the immunodef-ficiency syndrome. There are no convincing data about changes in natural killer (NK) activity in MM [4, 5]. Osteolysis is the second most frequently observed syndrome, and interleukin-1β (IL-1β), plays the main role in its development [6, 7]. IL-1β probably is also responsible for chronic renal insufficiency (CRI) [7, 8], which is of great prognostic value im MM [9]. Amyloidosis rarely appears in MM patients (6%–15%) [10]. The aims of this study were to clarify the role of LCIS, to determine NK activity of peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) and IL-1 production by peripheral blood monocytes (PBM) in MM, and to assess any possible correlation between these data and the course of MM.

Keywords

Toxicity Osteoporosis Leukemia Oncol Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yoshua DE (1988) Biology of multiple myeloma — host tumour interactions and immune regulation of disease activity. Hematol Oncol 6:83–86CrossRefGoogle Scholar
  2. 2.
    Wearne A, Yoshua DE, Kronenberg H (1985) Light chain isotype suppression — a new parameter. Aust NLY 15:629–633Google Scholar
  3. 3.
    Mills KHY, Cawley C (1983) Abnormal monoclonal antibody defined helper/suppressor T-cell subpopulation in multiple myeloma. Relationship to treatment and clinical stage. Br J Haematol 53:271–275PubMedCrossRefGoogle Scholar
  4. 4.
    Einhorn S, Ahre A, Blomoren H, et al (1982) Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon. Int J Cancer 30:167–172PubMedCrossRefGoogle Scholar
  5. 5.
    Gastl G, Niederwieser D, Masth C, et al (1984) Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood 74:288–295Google Scholar
  6. 6.
    Cozzolino F, Torcia M, Aldunucci D, et al (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380–387PubMedGoogle Scholar
  7. 7.
    Kawano Y, Yamamoto I, Iwara K, et al (1989) Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646–1649PubMedGoogle Scholar
  8. 8.
    Lovett DH, Szamel M, Ryan SL, et al (1986) Interleukin-1 and the glomerular mesanguim. I. Purification and characterization of a mesangial cell-derived auto-growth factor. J Immunol 136:3700–3705PubMedGoogle Scholar
  9. 9.
    Kyle KA (1988) Prognostic factor in multiple myeloma. Hematol Oncol 6:125–130PubMedCrossRefGoogle Scholar
  10. 10.
    Fiedler K, Duril BYM (1986) Primary amyloidosis associated with multiple myeloma. Am J Med 80:413–418CrossRefGoogle Scholar
  11. 11.
    Afanasiev BV, Podoltzeva EI, Morozova EV, et al (this volume) Prognostic factors in patients with multiple myeloma. In: R. Neth et al. (eds) Modern trends in human leukemia. Springer, Berlin Heidelberg New YorkGoogle Scholar
  12. 12.
    Weiler TH, Coons AH (1984) Fluorescent antibody studies with agents of varicella and herpes zoster phopagated in vitro. Proc Soc Exp Biol Med 86:789–794Google Scholar
  13. 13.
    Yoda Y, Kawakani Z, Shubuya A, Abe T (1988) Characterisation of natural killer cell cultured from human bone marrow cells. Exp Hematol 16:712–717PubMedGoogle Scholar
  14. 14.
    Rykova MP, Spirande IV, Zedgenidze MS, et al (1981) A new highly sensitive test for normal killers. Immunology (USSR) 3:88–90Google Scholar
  15. 15.
    Gery Y, Gesshon RK, Waksman BH (1972) Potentiation of the T-lymphocyte response to mytogens. I. The responding cells. J Exp Med 136:128–142PubMedCrossRefGoogle Scholar
  16. 16.
    Mizel SB, Oppenheim JJ, Rosenstreich DL (1978) Characterization of lymphokine-activation factor produced by the macrophage cell line p 388 D1. I. Enhancement of LAF production by activated T-lymphocytes. J Immunol 120:1497–1503PubMedGoogle Scholar
  17. 17.
    Wearne A, Yoshua DE, Young GAR, Kronenberg H (1987) Multiple myeloma: light chain isotype suppression — a marker of stable disease at presentation. Eur J Haematol 38:43–49PubMedCrossRefGoogle Scholar
  18. 18.
    Gerson M (1980) Systemic and in situ natural killer activity in tumour bearing mice and patients with cancer. In: Herbesman RB (ed) Natural killer mediated immunity against tumours. Academic, New York p 1047Google Scholar
  19. 19.
    Hercend T, Schmidt RE (1988) Characteristics and uses of natural killer cells. Immunol Today 10:241–244Google Scholar
  20. 20.
    Peest D, Vries J, Holscher K, Leo R, Deicher H (1989) Effect of interleukin-2 on the ex vivo growth of human myeloma cells. Cancer Immunol Immunother 30:227–232PubMedCrossRefGoogle Scholar
  21. 21.
    Gottleib D, Prentice G, Heslop H, et al (1989) Effect of recombinant interleukin-2 administration on cytotoxic function following high-dose chemotherapy for hematological malignancy. Blood 7:2335–2342Google Scholar
  22. 22.
    Shimazaki C, Aizpodien J, Wisniewski D, Gulati SC, Kolitz JE, Fried J, Clarhson BD (1988) Cell-mediated toxicity of interleukin-2 activated lymphocytes against autologous and allogeneic human myeloma cells. Acta Haematol 80:203–209PubMedCrossRefGoogle Scholar
  23. 23.
    Sone S, Inamura N, Nii A, Ogura T (1988) Heterogenity of human lymphokine (IL-2)-activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes. Int J Cancer 42:428–434PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • V. A. Almazov
  • E. I. Podoltzeva
  • E. V. Morozova
  • X. O. Sitskaya
  • V. M. Kravzova
  • B. V. Afanasiev
    • 1
  1. 1.1st Leningrad Medical Institute, USSR Petrov Research Institute of OncologyLeningradUSSR

Personalised recommendations